Sanaria Inc.
Sanaria is a Maryland-based biotechnology company focused on developing innovative malaria vaccines, especially targeting African children. Their mission is to develop, commercialize, and distribute an attenuated malaria sporozoite vaccine to prevent malaria-related illness and death. They engage in research, clinical trials, manufacturing, and global collaborations, including the i-PfSPZ-C consortium. Sanaria has received significant funding from grants, the Gates Foundation, and other sources, and has established manufacturing facilities to support vaccine development and clinical studies.
Industries
Nr. of Employees
medium (51-250)
Sanaria Inc.
9610 Medical Center Drive, Suite 200, Rockville, MD 20850
Patents
Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
US-11760794-B2
View Details
Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
US-11760794-B2
View DetailsProducts
Attenuated sporozoite malaria vaccine candidates
Vaccine candidates derived from radiation-attenuated Plasmodium falciparum sporozoites intended to prevent malaria infection and evaluated in human clinical trials.
Attenuated sporozoite malaria vaccine candidates
Vaccine candidates derived from radiation-attenuated Plasmodium falciparum sporozoites intended to prevent malaria infection and evaluated in human clinical trials.
Services
On-site clinical manufacturing and process development for clinical lots of attenuated whole-parasite vaccine material, including aseptic insect-based production, attenuation, harvesting, formulation and cold-chain storage.
Design and execution support for early-stage human trials, including safety evaluations, proof-of-concept studies and coordination of international trial sites and endemic-area studies.
Organization and facilitation of international research consortia to enable coordinated trial planning, data sharing, and centralized dissemination among academic, clinical and funding partners.
Preparation and administration of government- and philanthropically-funded research awards to support manufacturing validation, regulatory filings and clinical development programs.
On-site clinical manufacturing and process development for clinical lots of attenuated whole-parasite vaccine material, including aseptic insect-based production, attenuation, harvesting, formulation and cold-chain storage.
Design and execution support for early-stage human trials, including safety evaluations, proof-of-concept studies and coordination of international trial sites and endemic-area studies.
Organization and facilitation of international research consortia to enable coordinated trial planning, data sharing, and centralized dissemination among academic, clinical and funding partners.
Preparation and administration of government- and philanthropically-funded research awards to support manufacturing validation, regulatory filings and clinical development programs.
Expertise Areas
- Whole-organism attenuated parasite vaccine development (sporozoite-based)
- Clinical trial design and management, including Phase I/II and multi-site international studies
- Controlled human infection challenge models for efficacy assessment
- GMP clinical manufacturing and aseptic insect-based antigen production
Key Technologies
- Whole-organism attenuated parasite vaccine platforms
- Insect-based antigen production (mosquito rearing and infection)
- Irradiation-based attenuation
- Salivary gland parasite harvesting and aseptic downstream processing
News & Updates
Initial safety evaluations in clinical trials show promising results for the PfSPZ-LARC2 malaria vaccine.
The consortium meeting discussed research and future plans for malaria vaccines.
Dr. Stephen L. Hoffman received the prestigious medal for contributions to tropical medicine.
A publication highlighting the safety and efficacy of the malaria vaccine in pregnant women.
A new vaccine approach providing protection during pregnancy.
Dr. Stephen L. Hoffman recognized as the most cited author in the world for malaria research between 1995-2005.
Initial safety evaluations in clinical trials show promising results for the PfSPZ-LARC2 malaria vaccine.
The consortium meeting discussed research and future plans for malaria vaccines.
Dr. Stephen L. Hoffman received the prestigious medal for contributions to tropical medicine.
A publication highlighting the safety and efficacy of the malaria vaccine in pregnant women.
A new vaccine approach providing protection during pregnancy.
Dr. Stephen L. Hoffman recognized as the most cited author in the world for malaria research between 1995-2005.